

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Infectious disease</b>				
HIV/AIDS	HIV reverse transcriptase	<p>A study in cell culture and in rodents identified a non-nucleoside reverse transcriptase inhibitor (NNRTI) that could help treat HIV infection.</p> <p><i>In vitro</i>, 10-chloromethyl-11-demethyl-12-oxo-calanolide A had antiviral activity with nanomolar EC<sub>50</sub> values against multiple mutant HIV strains. Mice tolerated a single oral dose. Next steps include ongoing long-term toxicity studies.</p> <p>At least eight companies have NNRTIs in development stages ranging from preclinical to marketed to treat HIV/AIDS.</p> <p><b>SciBX 3(5); doi:10.1038/scibx.2010.155</b>  <b>Published online Feb. 4, 2010</b></p>	Patent and licensing status unavailable	<p>Xue, H. <i>et al. J. Med. Chem.</i>; published online Jan. 5, 2010; doi:10.1021/jm901653e</p> <p><b>Contact:</b> Gang Liu, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China            e-mail: <a href="mailto:gliu@imm.ac.cn">gliu@imm.ac.cn</a></p> <p><b>Contact:</b> Zhiwei Chen, The University of Hong Kong, Pokfulam, Hong Kong, China            e-mail: <a href="mailto:zchenai@hku.hk">zchenai@hku.hk</a></p>